Compare HBIO & NAII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HBIO | NAII |
|---|---|---|
| Founded | 1901 | 1980 |
| Country | United States | United States |
| Employees | N/A | 234 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.1M | 21.6M |
| IPO Year | 2000 | 1987 |
| Metric | HBIO | NAII |
|---|---|---|
| Price | $0.60 | $2.56 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 537.0K | 15.7K |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $87,371,000.00 | ★ $135,157,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.80 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 10.92 |
| 52 Week Low | $0.28 | $2.57 |
| 52 Week High | $1.43 | $4.96 |
| Indicator | HBIO | NAII |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 26.77 |
| Support Level | $0.53 | $3.32 |
| Resistance Level | $0.65 | $3.50 |
| Average True Range (ATR) | 0.04 | 0.33 |
| MACD | 0.01 | -0.11 |
| Stochastic Oscillator | 69.66 | 12.70 |
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Natural Alternatives International Inc is engaged in formulating, manufacturing, and marketing nutritional supplements. It offers vitamins, minerals, herbs, and other supplements, as well as other healthcare products, to customers within the United States and internationally. Its business activity is operated through Private-Label Contract Manufacturing and Patent & Trademark Licensing segments. The company derives the majority of revenue from Private-Label Contract Manufacturing, which is engaged in providing manufacturing services to companies that market and distribute nutritional supplements and other healthcare products, whereas the Patent and Trademark Licensing segment includes royalty income from its license and supply agreements associated with the sale.